Oncolytics Biotech Inc T.ONC

Adlai Nortye Ltd prices offering at US$23 per share

[Noteable]

Adlai Nortye Ltd announced the pricing of its initial public offering of 2,500,000 American depositary shares (“ADSs”), at a public offering price of US$23.00 per ADS.

• American Depositary Shares (ADS) refer to shares in foreign companies that are held by U.S. depositary banks and can be traded in the U.S., including on major exchanges.
• The terms American Depositary Shares and American Depositary Receipts are often used interchangeably.
• ADSs allow foreign companies access to a wider investor base and the world's most sophisticated financial marketplace.
• The main drawback of ADSs for investors is that there is still some currency risk, even though they are denominated in U.S. dollars.
•  

https://www.biospace.com/article/releases/adlai-nortye-ltd-announces-pricing-of-initial-public-offering-september-29-2023/

[Noteable]

All of the ADSs were offered by Adlai Nortye. In addition, an investor will acquire a total of 5,217,391 Class A ordinary shares from Adlai Nortye in a private placement concurrent with the closing of the public offering at the same per share purchase price. Adlai Nortye expects to receive aggregate gross proceeds of US$97.5 million, including US$57.5 million from the public offering (before

[Noteable]

Cantor Fitzgerald & Co. is acting as sole book-running manager for the public offering. Now ask yourself what the value of ONCY is 

[Noteable]

This speaks to overwhelming fact that the trading of ONCY shares is being significantly manipulated.

[Noteable]

And if that is the case that then shareholders must really question their trust in ONCY management.

[Noteable]

 Should read: .... if that is the case, then shareholders must really question their trust in ONCY management.

[Moondance]

Noteable - I really respect your comments - can you expand on this please

[fox7mf]

I'm not speaking for Noteable, but I would suggest that shareholder value certainly isn't the first & foremost goal for glory hound Coffey. Two ph3 trials in PDAC alone. Two more ph3 trials in mBC and (possibly) CRC. Our market cap should be approaching $4b. My opinion only.

[inthno]

Hey Fox, I agree but markets are fickle so IF ESMO comes out with good results and confirms the panc and we get pfs and general OS numbers and they are good and IF the crc is showing that signal to move forward then really I cannot see any way that the sp will not start to move. Also around the timeframe we could finally see the definitive agreements done and signed and if the fda approves the

[Moondance]

Sorry Noteable - this is the comment I was hoping to get more understanding from you on:  re: Adlai pricing their shares at $23 "And if that is the case that then shareholders must really question their trust in ONCY management."

[Noteable]

Moondance: Trust can be gained or lost by the turn of a word or phrase. Saying that ONCY's last capital raise was primarily taken up by a "large healthcare institutional buyer" as ONCY's press release alluded to,  is the same as saying that Cannacord, which happens to be a large institutional buyer of healthcare company stocks, bought the deal to cover its large short

[Noteable]

I would also say that ONCY needs to better manage expectations, and avoid any real or perceived opacity or appearance of intent to confuse in any future communications. 

[Moondance]

Thank you

[Quentin30]

excellent, now there is another way to lose money on ONCY...!!